Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...

Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The regulatory body approved finerenone for the treatment of adult patients with ...

A Bayer drug the company frames as key to growing its cardiovascular portfolio has expanded its FDA approval to a type of heart failure, a new indication that keeps this pill on the path to achieving ...

Data to be presented include two subgroup analyses from the pivotal Phase III FINEARTS-HF trial, which assessed the safety and efficacy of finerenone versus placebo in heart failure (HF) patients with ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure. Bayer on Monday ...

Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to treat patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%, 1 ...

China's National Medical Products Administration (NMPA) approved the expanded use of Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) Kerendia to include earlier stages of chronic kidney disease (CKD) linked with ...